---

Antihyperlipidemic Effect of Microbially Converted Eicosapentaenoic Acid from Rice Bran Oil in Rats

---

Original Article

Author Details : Shilpa A. Deshpande, Nandkishor J. Duragkar

Volume : 3, Issue : 1, Year : 2016

Article Page : 24-28

Suggest article by email

Get Permission

---

Abstract

Objective: Eicosapentaenoic acid (EPA) from fish oil is known to have favourable effects on cardiovascular system by lowering the elevated lipid levels. With the intention of producing an alternative vegetarian source to fish EPA, we have microbially synthesized EPA (mEPA) from ?- linolenic acid (ALA) isolated from rice bran oil which was spectroscopically analysed. The objective of the present study was to evaluate the effect of mEPA on lipid profile in experimentally induced hyperlipidemic rats.
Methods: Animals were divided into 12 groups of six animals each; control being treated with vehicle, 6 groups received normal diet while 6 groups received high fat diet. Both treatment groups received standard drug Atorvastatin (10 mg/ kg in saline, p.o.); three different doses of EPA (5, 10 and 50 mg/kg) and fish oil (1 g/ kg) for 28 days and were compared with sham hyperlipidemic rats. The hyperlipidemia was induced by high fat diet and lipid profile was estimated. 
Results: The elevated levels of LDL, VLDL and triglycerides in high fat diet induced animals were found to be decreased in the treatment groups whereas the decreased levels of HDL in hyperlipidemic group were significantly increased in the mEPA treated groups. The atherogenic index was improved with mEPA treatment.
Conclusion: mEPA has shown promising antihyperlipidemic effect and can fulfil the need of alternative vegetarian source of EPA than fish oil to be used in the hypertensive hyperlipidemic conditions.

Key words: Antihyperlipidemic, Eicosapentaenoic acid, hyperlipidemia, High fat diet, Lipid profile

How to cite : Deshpande S A, Duragkar N J, Antihyperlipidemic Effect of Microbially Converted Eicosapentaenoic Acid from Rice Bran Oil in Rats. Indian J Pharm Pharmacol 2016;3(1):24-28

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.